-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FHhSXZu999mZzuYh+fQ/g2ujCY3ln2sz38HdNnDLxyqc7crJ7wTaKUkFN2+/EW8d Um64V3ryHP/AYPbBVYFSYA== 0001014156-04-000005.txt : 20040603 0001014156-04-000005.hdr.sgml : 20040603 20040603153332 ACCESSION NUMBER: 0001014156-04-000005 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20040331 FILED AS OF DATE: 20040603 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SAVIENT PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000722104 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 133033811 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 BUSINESS PHONE: 7324189300 MAIL ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 FORMER COMPANY: FORMER CONFORMED NAME: BIO TECHNOLOGY GENERAL CORP DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WATTLETON FAYE CENTRAL INDEX KEY: 0001014156 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-15313 FILM NUMBER: 04847198 BUSINESS ADDRESS: STREET 1: 25 WEST 43RD STREET STREET 2: SUITE 1014 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 212 391 7718 MAIL ADDRESS: STREET 1: 767 FIFTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10153 4/A 1 edgar.xml PRIMARY DOCUMENT X0202 4/A 2004-03-31 2004-04-02 0000722104 SAVIENT PHARMACEUTICALS INC SVNT 0001014156 WATTLETON FAYE 300 CENTRAL PARK WEST APT. 15H NEW YORK NY 10024 1 0 0 0 Common stock, $.01 par value per share 2004-03-31 4 A 0 652 3.83 A 5056 D Options to purchase common stock, $.01 par value per share 3.83 2004-03-31 4 A 0 5000 3.83 A 2005-03-31 2014-03-31 Common stock, $01 par value per share 5000 85625 D These shares were granted pursuant to the Company's Stock Compensation Plan for Outside Directors, which provides for the grant to non-employee directors of that number of shares of Common Stock having an aggregate fair market value on the last business day of each quarter equal to $2,500, until he is no longer an Outside Director. On March 31, 2004, the fair market value of the Common Stock, based on the closing price, was $3.83. These options will become fully vested and immediately exercisable on 03/31/2005. The Form 4 filed on 4/2/04 showed an incorrect number of derivative securities held following the 3/31/04 option grant, i.e., 95,000. The correct number is 85,625 as reflected in this amended Form 4. Beata Smith as Attorney-in-Fact for Faye Wattleton 2004-06-03 -----END PRIVACY-ENHANCED MESSAGE-----